Share This Page
CRYPTENAMINE TANNATES - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for cryptenamine tannates and what is the scope of patent protection?
Cryptenamine tannates
is the generic ingredient in one branded drug marketed by Medpointe Pharm Hlc and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for CRYPTENAMINE TANNATES
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | CRYPTENAMINE TANNATES at DailyMed |
US Patents and Regulatory Information for CRYPTENAMINE TANNATES
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medpointe Pharm Hlc | UNITENSEN | cryptenamine tannates | TABLET;ORAL | 009217-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Cryptenamine Tannates: Market Dynamics and Financial Trajectory
Cryptenamine tannates is a dated pharmaceutical product class whose commercial footprint appears limited and fragmented. Public-facing market analytics (sales, revenue, pricing, volumes) are not available in a way that supports a defensible financial trajectory across geographies. What can be established from the observable record is that availability, regulatory status, and distribution are largely legacy-driven and tied to older therapeutic indications, which constrains modern portfolio value and investor-relevant forecasting.
What does the market look like in practice?
1) Product identity and market scope
- “Cryptenamine tannates” is typically treated as a branded drug-name variant associated with cryptenamine (often in the context of urinary/antispasmodic or related use patterns historically).
- Market presence today is best characterized as low-visibility and legacy supply, not as an actively promoted global blockbusting product.
- Across major analytics sources (public market trackers, payer databases, and patent-research registries), the compound name appears too sparse for a clean, consistent series of sales and units that can be mapped to a credible financial trajectory.
2) Supply chain reality
- Products in this category usually behave like older, off-patent small molecules where price competition and distribution rationalization dominate.
- That structure tends to create:
- Thin sales reporting (small lots, limited-country sales, sporadic tender participation)
- Volatile pricing at the margin (currency, tender formats, wholesaler markups)
- Short-run commercial survival rather than multi-year, compounding growth
3) Competition dynamics
- For older antispasmodic/uro-related small molecules, the competitive set is not dominated by one peer brand. It is dominated by:
- Generic substitutes
- Alternative therapeutic classes that gained share over time (newer symptom and infection management approaches)
- Formulation-specific competitors when routes differ (tablets vs. syrups vs. combination products)
Implication for market dynamics: cryptenamine tannates behaves like an off-cycle legacy line where demand persistence depends on niche formularies, habitual prescriber use, and supply continuity rather than on differentiation.
What drives demand for cryptenamine tannates?
Primary demand drivers
- Formulary persistence in lower-to-middle income markets where legacy generics maintain procurement continuity.
- Prescriber inertia for long-established dosing regimens.
- Manufacturing availability: if one supplier exits a market, supply shocks can swing volumes for the remaining seller.
Demand constraints
- Therapeutic modernization: newer standards-of-care in urinary symptoms and related indications reduce incremental demand.
- Regulatory friction: older dossier/variation structures can increase renewal and compliance costs.
- Switching pressure: generic substitution is the baseline in many markets once patents expire.
Commercial effect: demand tends to show slow decay (or flatlining) rather than cyclical expansion, unless a specific country tender or hospital procurement line sustains volume.
How should the financial trajectory be modeled?
Because the observable data does not support a defensible sales time series, the only financially actionable path is a scenario-based trajectory tied to typical legacy/off-patent behavior. The market behavior is consistent with a profile of:
Base-case pattern (common for legacy off-patent medicines)
- Near-term stability where the product remains stocked
- Gradual erosion where formularies update or procurement shifts to newer options
- Margin compression from generic competition and tender price pressure
- Limited re-acceleration unless reformulation or new indication creates a new demand pocket
Adverse-case pattern
- Supplier consolidation leads to intermittent availability
- Tender-driven price suppression accelerates
- Volume declines faster than margin improvement can offset
Upside-case pattern
- A small number of markets maintain strong procurement continuity
- Supply stability is maintained, and substitution is delayed in practice
Financial trajectory conclusion: the product’s likely value creation is more about continued defensible supply and low-cost distribution than about growth. For investors, that means focusing on channel survival and procurement exposure rather than blockbuster-like uptake.
What is the patent and exclusivity landscape impact on finance?
A true financial trajectory is tied to exclusivity, but here the product class is treated as legacy/off-patent in commercial practice. That structure drives several investment-relevant outcomes:
- No sustained premium pricing beyond legacy brand or procurement rules
- No long runway for revenue scaling tied to regulatory exclusivity
- Higher probability of margin squeeze as generic competition consolidates
The business effect is that even if demand is stable in units, profitability often trends downward unless the company holds cost or supply advantages.
Market-by-market dynamics: what tends to happen by country type?
1) Tender-heavy markets
- Price becomes the main determinant of volume.
- Financial outcomes follow the pattern:
- Lower ASP (average selling price)
- Stable or declining unit volumes depending on tender allocations
- Margin compression unless a supplier secures dominant quota
2) Formularies with entrenched generics
- Volumes can hold longer, but price still declines over time.
- Financial outcomes:
- Flat units for longer
- Gradual declines in revenue per unit
- Occasional spikes around procurement cycles
3) Regulated reimbursement regimes
- If cryptenamine tannates remains reimbursed, it can maintain steady sales.
- If reimbursement is restricted, it can drop quickly.
- Financial outcomes:
- Revenue follows reimbursement policy more than clinical practice
What are the actionable commercial levers?
For a legacy molecule line like cryptenamine tannates, the levers that matter are operational and portfolio-positioning, not R&D differentiation:
- Supply continuity: keep availability across core markets to prevent permanent substitution.
- Tender strategy: compete for quota at sustainable landed cost, not just nominal price.
- Formulary access: focus on repeat procurements and audit-proof documentation.
- Cost structure: protect gross margin by optimizing manufacturing and distribution.
These levers determine whether the product generates cash through steady procurement or becomes a low-visibility, margin-thin SKU.
Financial trajectory summary in decision-ready terms
Likely trajectory profile
- Revenue growth: low to none; primarily flat-to-declining
- Unit trend: stable in niche markets; declining where formularies modernize
- ASP trend: downward due to generic substitution and tender dynamics
- Gross margin: pressured, improves only through cost leadership or supply dominance
- Sustainability: dependent on continuous stock availability and policy support
Investment framing
- Treat cryptenamine tannates as a cash-stable legacy line at best, not as a growth engine.
- The key risk is availability-driven permanent demand loss.
- The key value driver is cost and procurement execution.
Key Takeaways
- Cryptenamine tannates appears to operate as a legacy, low-visibility off-patent medicine with fragmented market presence, limiting the ability to produce a credible, data-backed global financial trajectory.
- Market dynamics are dominated by generic substitution, tender procurement, and supply continuity, not clinical differentiation.
- The financially actionable outlook is flat-to-declining revenue with margin pressure, unless the seller holds a strong cost advantage and secures recurring quota in core markets.
FAQs
1) Is cryptenamine tannates a growth-market drug?
No clear evidence supports growth-market dynamics. The commercial pattern is consistent with legacy/off-patent behavior where demand is stable only in niche channels and pricing trends downward.
2) What drives near-term sales more: clinical adoption or procurement?
Procurement and reimbursement channel continuity typically drive short-run outcomes more than new clinical adoption for legacy medicines.
3) How does generic competition affect pricing?
It pushes ASP down through substitution and tender price competition, compressing margins unless cost leadership exists.
4) What is the biggest operational risk for a legacy SKU?
Supply interruption. Lack of availability can cause switching that does not revert quickly after stock returns.
5) What role does patent exclusivity play in this product’s financial outlook?
If exclusivity is absent, there is limited ability to sustain premium pricing and revenue scaling, making profitability dependent on execution and cost position.
References
[1] World Health Organization. WHO Model List of Essential Medicines. Geneva: WHO. (Accessed via WHO essential medicines resources.)
[2] U.S. Food and Drug Administration. Drug Approval Reports / Orange Book (legacy context search). Silver Spring, MD: FDA.
[3] European Medicines Agency. European public assessment reports and medicines database. Amsterdam: EMA.
More… ↓
